2

This presentation contains certain forward-looking statements. These statements relate to future events or future performance and reflect management’s expectations and assumptions regarding growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. A number of factors could cause actual events to differ materially. In evaluating these statements, prospective purchasers should specifically consider various risks as more fully outlined in the prospectus, a copy of which can be obtained online at www.sedar.com.

Forward Looking Statements

2

3

� Skin cancer strikes 1 in 5 in the U.S.1

� It is the most common form of cancer

� 40-50% of Americans who live to 65 expected to get skin cancer 2

� Melanoma kills one person every hour in the US 3

� Melanoma is the #1 cancer killer of women 25-30 4

� Incidence of melanoma rising faster than any other cancer 5

� Melanoma accounts for 75% of skin cancer deaths 6

- Howard Rogers, Dermatologist, Lead on Medicare research

“There’s an epidemic of skin cancer”

3

Which one of these lesions is melanoma?

4

Early detection vital to saving lives

0

20

40

60

80

100 99% Melanoma Five Year Survival Rate by Tumor Stage 6

15%

Stage I Stage II Stage III Stage IV

5

� 2 million Americans get skin cancer each year 7

� Treating melanoma alone costs $1.5 billion annually in the U.S. 8

� Advanced stage melanoma significantly more

costly to treat than early stage › Approximately $1,800 to treat early stage

melanoma, and $170,000+ to treat late stage melanoma

Early detection would save billions of dollars

6

� Primary diagnosis done by GPs with varying levels of experience

� Full body examinations seldom conducted

� 33.8% sensitivity for melanoma for GPs 9 › Squamous Cell Carcinoma – 41.1% › Basal Cell Carcinoma – 63.9%

� Biopsies invasive and costly

› Permanent scarring

� ~80% of biopsies test negative 10

Current skin cancer detection methods limited

Clinical Diagnosis

Punch Biopsy

Histological Diagnosis

7

� Detects melanoma with 99% sensitivity vs. 33.8% for primary clinical diagnosis 11

� Approved for sale in Canada, the EU, and Australia

� Winner of Popular Science “Best of What’s New 2011” award

� Developed by BC Cancer Agency and UBC

� Patented technology

� Exclusively licensed to Verisante Technology, Inc.

� Technology applied via endoscope to gastrointestinal, lung, and

cervical cancers

Initial Focus: skin cancer detection Breakthrough cancer detection system

8

Skin cancer: Verisante AuraTM Highly automated detection process

te AuraTM

Near Infrared Raman Spectroscopy

Handheld probe scans for 21 spectral markers in an instant

Rapid speed enables full body scans

Provides data on chemical composition of skin based on molecular vibrations

Differentiates between malignant and benign tissue

Pathology on every lesion scanned

9

Skin cancer: Verisante AuraTM Highly automated detection process

Safe, Non-invasive, Fast

Real time results 99% sensitive for all major skin cancers

Increased survival rates

Reduced treatment costs

Reduced unnecessary biopsies Reduced waiting times

10

� 6 year clinical study at Vancouver General Hospital’s Skin Care Center

� Focused on differentiating cancerous lesions from benign lesions

� 1,000 skin lesions scanned

� Clinical study published in major peer reviewed journal Cancer Research

Skin cancer: Verisante AuraTM Proven in clinical trial by UBC Dept. of Dermatology

Melanoma

99% sensitivity 15% specificity 95% sensitivity 38% specificity

Cancerous and Precancerous Lesions

99% sensitivity 17% specificity 95% sensitivity 41% specificity

11

Superior technology over competition

Verisante Aura™ Mela Sciences MelaFind™

Detects Melanoma, SCC, BCC, AK Detects Melanoma

NIR Raman Spectrometer Computerized Imaging Technology

Extensible platform technology No platform technology

Approved in Can, EU, Aus Approved in US, EU

99% Sensitivity; 17% Specificity 98% Sensitivity; 9.5% Specificity

1 second to scan lesion 2 minutes to scan lesion

Small probe Large probe

$10 disposable tip per patient $50 memory card per lesion

For use by all medical professionals For use by dermatologists only

12

Skin cancer: Verisante AuraTM Clear regulatory pathway to commercialization

2012 2013 2014 2015

Sales Revenue

Sales Revenue

FDA Approval & Revenue

Production Engineering

Clinical Study PMA

Production Engineering

13

Skin cancer: Verisante AuraTM Significant market potential with multiple end users

Canada

USA

EU

South Africa

Australia NZ

Initial Geographic Markets Recurring revenue from sale of disposable probe tips

Staged Rollout Strategy

STEP 1

Early adopters ~32,000 Dermatologists

STEP 2

Innovators ~950,000 General Practitioners

STEP 3

Skin Care Clinics Oncology and Imaging Clinics

HMOs

14

Will drive broader market acceptance Initial focus on early adopters and innovators

0

400

800

1200

1600

2000

Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

Targeting 14% penetration by year 5 Dermatologists

Canada, European Union, South Africa, Australia, New Zealand

United States

15

Will drive broader market acceptance Initial focus on early adopters and innovators

General Practitioners

Canada, European Union, South Africa, Australia, New Zealand

United States

0

5000

10000

15000

20000

25000

30000

35000

Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

Targeting 6% penetration by year 5

16

� Clinical study underway at VGH for lung cancer detection › Pilot study results demonstrated remarkable

96% sensitivity and 91% specificity 12

› Technology named a “Top 10 Cancer

Breakthrough of 2011” by the Canadian Cancer Society

› Technology may also be applied to gastrointestinal and cervical cancers

Verisante CoreTM Endoscopic system enables detection of other cancers

Lung Cancer is the world’s #1 cancer killer with 1.4 million deaths/year 13

90%

1% 0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Early Stage Diagnosis Late Stage Diagnosis

Lung Cancer 5 Year Survival Rate: Early Stage vs Late Stage Diagnosis 14,15

17

As of March 15, 2012 Share Capital

Common Shares 56,195,592

Escrowed Shares (held by Founders) 8,403,000

Total Common Shares Outstanding 64,598,592

Warrants 13,838,125

Incentive Stock Options 4,659,570

Fully Diluted Share Capital 83,096,287

18

Market Comparables

Company Current Share Price

Est. 1yr Target Price Market Capitalization

MELA Sciences, Inc. (NASDAQ: MELA) $4.69 $12.80 $138,940,000

Novadaq (TSX: NDQ) $7.00 $6.56 $229,210,000

ALI Technologies Inc. *Sold to McKesson (NYSE: MCK) in 2002 for $530 Million

$530,000,000

19

Dr. Branko Palcic Ph.D.

• Honorary Professor, Dept. of Pathology and Laboratory Medicine, UBC • Founder, Cancer Imaging and Technology Departments, BC Cancer Agency • Co-inventor of LIFE-Lung device, used in over 150 major medical centers world-wide • Friesen-Rygiel Award for Outstanding Canadian Academic Discovery (1999) • King George V Silver Jubilee Cancer Research Fellow

Dr. Haishan Zeng Ph.D.

• Senior Scientist, Integrative Oncology Dept. BC Cancer Agency • Associate Professor, Dermatology and Skin Science, University of British Columbia • Co-inventor - Verisante™ technology

Focused on developing systems for the early detection of cancer Strong scientific pedigree

20

Dr. David McLean MD, FRCPC

• Professor, Dept. of Dermatology and Skin Science, UBC • President, Cancer Prevention Institute of Canada • Secretary-General, International Foundation for Dermatology • Former President, Current Board member, International League of Dermatological Societies • Former President, Canadian Dermatology Association • Co-inventor - Verisante™ technology

Dr. Harvey Lui MD, FRCPC

• Professor and Head, Dept. of Dermatology and Skin Science, UBC • Former Clinical Fellow, Massachusetts General Hospital, Harvard Medical School • University Killam Prize (2001) • Secretary-General, World Congress of Dermatology • Co-inventor - Verisante™ technology

Focused on developing systems for the detection of cancer Strong scientific pedigree

21

Thomas Braun BA, JD, LLM – Chief Executive Officer

• Public company experience • Extensive experience in executing M&As and raising capital • Advised high tech companies on international business transactions • Expertise in technology licensing • Member, California Bar Association and Law Society of British Columbia

Anna Trinh B.Comm, LLB – Chief Financial Officer and Corporate Counsel

• Experience in counseling companies on regulatory and compliance filings • M&A and financial transaction experience • Practiced corporate securities law in private practice • Member, Law Society of British Columbia

Focus: controlling costs, accelerating product development & regulatory approval process

Experienced management

22

Strong, independent Board of Directors

Joe Biegel BS, MS (Medical Imaging)

• Vice-President, Product Management & Marketing • McKesson Medical Imaging Group • Senior positions with Agfa Healthcare, Hewlett

Packard, Polaroid Medical Imaging

Chris Dennis MBA

• President and CEO, Novadent Inc. • Senior positions with Angiotech

Pharmaceuticals, Johnson & Johnson / Ortho Neutrogena

Jake Thiessen Ph.D.

• Professor Emeritus, University of Toronto • Founding Director, School of Pharmacy and

Health Sciences Campus, University of Waterloo

Karen Boodram BSc, MBA

• President, BioManna Consulting • Former Life Sciences Analyst, PI Financial • More than 25 years healthcare experience • Ten years with Novartis

23

� Patented technology with exclusive worldwide license from BC Cancer Agency

� AuraTM: a breakthrough skin cancer detection device › Approved for sale in Canada, 27 member EU Nations, and Australia › FDA approval process started January 2012 › Featured as a top technology innovation in Popular Science’s “Best of What’s New” (2011)

� Clear regulatory pathway to commercialization with significant market potential

� CoreTM endoscopic device for detection of lung cancer in clinical trials › Recognized by the Canadian Cancer Society as a “Top 10 Cancer Breakthrough of 2011”

� Strong scientific pedigree and experienced management

� Verisante Technology, Inc. named 2012’s top ranking Technology and Life Sciences Company on the TSX Venture 50

Summary

24

References End Notes

1. American Cancer Society: Cancer Facts & Figures 2009

2. National Cancer Institute: Cancer Trends Progress Report 2007, Update April 2008

3. American Cancer Society: Cancer Facts and Figures 2009

4. Melanoma Research Foundation

5. National Cancer Institute: SEER Cancer Statistics Review, 1975-2004

6. National Center for Chronic Disease Prevention and Health Promotion

7. Rogers H.W., Weinstock M.A., et al.: Incidence Estimate of Non Melanoma Skin Cancer in the U.S., 2006. Archives of Dermatology 2010

8. National Cancer Institute: Cancer Trends Progress Report 2007

9. Heal C.F., Raasch B.A., Buettner P.G., Weeden D.: Accuracy of Clinical Diagnosis of Skin Lesions. British Journal of Dermatology 2009

10. Jones T.P., Boiko P.E., Piepkorn M.W.: Skin biopsy indications in primary care practice: a population-based study. JABFP 1996; 9:397–404

11. Lui H., Zhao J., McLean D.I., Zeng H.: Real-time Raman spectroscopy for in vivo skin cancer diagnosis. Cancer Research Published

OnlineFirst March 20, 2012

12. Short M., Lam S., McWilliams A., Ionescu D., Zeng H.,: Using Laser Raman Spectroscopy to Reduce False Positives of

Autofluorescence Bronchoscopies, A Pilot Study. Journal of Thoracic Oncology 2011;6: 1206–1214

13. Cancer Research UK

14. Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition. Retrieved 2007-08-15.

15. Ishida T, Inoue T, Sugio K, Inoue K, Inuzuka S, Tateishi M, Sugimachi K.: Early squamous lung cancer and longer survival rates

Contact: #306 – 2309 West 41st Ave Vancouver, BC V6M 2A3 Tel 604.605.0507 Fax 604.605.0508 Email info@verisante.com www.verisante.com TSX-V: VRS OTCQX: VRSEF FRANKFURT: V3T